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Proteasomes degrade most of the proteins inside eukaryotic cells, including transcription factors and
regulators of cell cycle progression. Here we show that nanomolar concentrations of lactacystin, a specific
irreversible inhibitor of the 20S proteasome, inhibit development of the exoerythrocytic and erythrocytic stages
of the malaria parasite. Although lactacystin-treated Plasmodium berghei sporozoites are still invasive, their
development into exoerythrocytic forms (EEF) is inhibited in vitro and in vivo. Erythrocytic schizogony of P.
falciparum in vitro is also profoundly inhibited when drug treatment of the synchronized parasites is prior, but
not subsequent, to the initiation of DNA synthesis, suggesting that the inhibitory effect of lactacystin is cell
cycle specific. Lactacystin reduces P. berghei parasitemia in rats, but the therapeutic index is very low. Along
with other studies showing that lactacystin inhibits stage-specific transformation in Trypanosoma and Enta-
moeba spp., these findings highlight the potential of proteasome inhibitors as drugs for the treatment of
diseases caused by protozoan parasites.
The development of new antimalarial drugs is an urgent
priority considering the increasing prevalence of drug-resistant
Plasmodium falciparum parasites and the absence of effective
vaccines or of vector control measures (3). Malaria infection is
initiated when Plasmodium sporozoites are injected into the
bloodstream of the host by an infected anopheline mosquito.
Shortly after, sporozoites enter hepatocytes where they de-
velop into exoerythrocytic forms (EEF). Each EEF contains
thousands of merozoites which rupture from the hepatocyte
and invade erythrocytes. In the erythrocytic cycle of P. falcipa-
rum, which lasts 48 h, merozoites mature into trophozoites and
then into schizonts. A mature schizont contains between 8 and
26 merozoites, each of which is capable of infecting a new
erythrocyte.
During both its hepatic and erythrocytic stages the parasite
undergoes radical morphological changes and many rounds of
replication, events that likely require proteasome activity. Pro-
teasomes are major components of the eukaryotic cellular ma-
chinery (5, 18, 23, 28), mediating the normal turnover of pro-
teins and the degradation of proteins that have been
improperly folded or denatured (29). In addition to these
housekeeping functions, proteasomes play a key role in cell
cycle progression (20) and the regulation of numerous tran-
scription factors (24).
Studies of proteasome function have been facilitated by the
availability of lactacystin, a highly specific inhibitor of protea-
some proteolytic activity. Lactacystin is a Streptomyces metab-
olite whose active form binds irreversibly to the catalytic
threonines in the active sites of the b subunits of the protea-
some (6, 9, 12, 16). Previous studies have shown that lactacystin
affects the stage-specific transformation of Trypanosoma cruzi
trypomastigotes into amastigotes (15) and the encystation of
Entamoeba invadens (14). Here we use lactacystin to study the
role of proteasomes in the life cycle of malaria parasites.
MATERIALS AND METHODS
Drugs. Lactacystin and lactacystin analogs were synthesized as previously
described (4, 13, 22). 7-Ethyl lactacystin and des-7-methyl lactacystin were syn-
thesized in the Harvard laboratory. All drugs, except clasto-lactacystin b-lactone,
were dissolved in H2O to 1 mM and stored at 4°C until use. clasto-lactacystin
b-lactone was solubilized in dimethyl sulfoxide to 10 mM and stored at 220°C
until use. Lactacystin for injection into rats was dissolved in phosphate-buffered
saline (PBS), pH 7.4, immediately before use.
Assay for EEF development in vitro. This assay was performed as described
previously (19) with a few modifications. Briefly, HepG2 cells (ATCC HB8065;
American Type Culture Collection, Manassas, Va.) were plated in chamber
slides (model 4808; Lab-tek, Naperville, Ill.) 48 h before each experiment. Plas-
modium berghei sporozoites were dissected from mosquito salivary glands and
resuspended in Dulbecco modified Eagle medium (Gibco BRL, Gaithersburg,
Md.) supplemented with 10% fetal calf serum (HyClone Laboratories, Logan,
Utah) and 20 mM HEPES (Sigma, St. Louis, Mo.). Approximately 50,000 sporo-
zoites were added per well, and the parasites were allowed to adhere to and
invade the HepG2 cells for 2 h. The wells were washed, and the cells were grown
for an additional 2 days after which they were fixed with methanol. The EEF
were then revealed with monoclonal antibody (MAb) 2E6 (34) followed by goat
anti-mouse immunoglobulin (Ig) conjugated to horseradish peroxidase (Accu-
rate Chemical Corp., Westbury, N.Y.) and 3,39-diaminobenzidine (Sigma). The
EEF in each well were counted microscopically with a 203 light microscope
objective.
Microscopic assay for quantification of sporozoite invasion. This assay was
conducted according to the method described by Renia et al. (27) with a few
modifications. HepG2 cells were plated in chamber slides as described above. P.
berghei sporozoites were pretreated with 3 mM lactacystin in Dulbecco modified
Eagle medium-fetal calf serum for 1 h at room temperature, washed, and then
added to the HepG2 cells. Controls were pretreated with medium alone. The
parasites were incubated with the HepG2 cells for 1 h at 37°C in 5% CO2. The
unattached sporozoites and medium were then removed, and the cells were fixed
with 4% paraformaldehyde. The extracellular parasites were revealed by incu-
bation with MAb 3D11 followed by goat anti-mouse Ig conjugated to rhodamine
(Boehringer Mannheim, Indianapolis, Ind.). The HepG2 cells were then perme-
abilized with methanol, and all parasites (intra- and extracellular) were revealed
with MAb 3D11 followed by goat anti-mouse Ig conjugated to fluorescein iso-
thiocyanate (FITC; Boehringer Mannheim). MAb 3D11 binds to the repeats of
the P. berghei circumsporozoite protein (38), found on both sporozoites and EEF
(32). The slides were mounted, and each field was counted with two different UV
filters so that both FITC-labeled and rhodamine-labeled sporozoites could be
counted. Between 40 and 50 fields were counted per well. The percent invasion
for each well was calculated from the following equation: [(total number of
parasites 2 number of extracellular parasites)/total number of parasites] 3
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100 5 % invasion, where the total number of parasites is the number of FITC-
labeled sporozoites and the number of extracellular parasites is the number of
rhodamine-labeled sporozoites.
Assessment of C-type rRNA switching to A-type rRNA. HepG2 cells (2.5 3 105
cells/well) were plated in 24-well plates (Falcon; Becton Dickinson, Franklin
Lakes, N.J.) and allowed to grow for 2 days. P. berghei sporozoites were incu-
bated with 3 mM lactacystin or without lactacystin for 15 min at room temper-
ature, and then 20,000 sporozoites were added to each well. After 2 h the
medium was removed and fresh medium without inhibitor was added. At 5 and
21 h after infection, the cells from each well were trypsinized, spun at 300 3 g,
and resuspended in 1 ml of Tri-Reagent (Sigma) and total cellular RNA was
extracted according to the manufacturer’s instructions. Reverse transcriptase
PCR (RT-PCR) was performed with an RT-PCR kit (Perkin-Elmer, Branch-
burg, N.J.). Total RNA was quantified by measuring the absorbance at 260 nm,
and RT reactions were performed with 0.1 mg of RNA and random hexamers
supplied by the manufacturer. PCR for this cDNA was performed with primers
specific for either C- or A-type rRNA. These primers were designed based on
published sequences (17) and included a 59 primer common to both types of
rRNA (59-GCCTGAGAAATAGCTACCACATC-39) and a 39 primer specific
for either A-type rRNA (59-CATGAAGATATCGAGGCGGAG-39) or C-type
rRNA (59-GGATAAAAGCAGTGACAGAAGTC-39). Relative amounts of C-
and A-type rRNA in each starting sample were estimated by performing PCR
with serial dilutions of the cDNA.
Culture of erythrocytic stages. P. falciparum 3D7 erythrocytic stages were
cultured by standard methods (25, 33) except that the culture medium contained
0.5% Albumax I (Gibco) in place of human serum.
[3H]hypoxanthine uptake assay. Parasites were synchronized with 5% sorbitol
(Sigma) (21) by two treatments, 30 h apart, resulting in approximately 90%
synchrony. Parasites were used 18 h after the second treatment. In the standard
assay (7), [3H]hypoxanthine (Amersham, Arlington Heights, Ill.), 0.5 mCi/well,
and drugs at the concentrations indicated in Fig. 5 were added at the time of
plating. For the time course assay, the [3H]hypoxanthine, with or without 0.6 mM
lactacystin, was added at the time points indicated in Fig. 6. Two sets of negative
controls were included in the experiments; one contained uninfected erythro-
cytes and label, and the other contained label and medium alone. Plates were
incubated at 37°C for 24 h and harvested onto glass fiber filters (Wallac Oy,
Turku, Finland) with a 1295-001 cell harvester (Wallac Oy), and the filters were
counted in a 1205 Betaplate (Wallac Oy) liquid scintillation counter. All treat-
ments were performed in triplicate wells.
Parasite growth in erythrocytes pretreated with lactacystin. Three milliliters
of packed, washed human erythrocytes was resuspended at a 50% hematocrit in
RPMI 1640 and incubated with 10 mM lactacystin or without lactacystin for 1 h
at 37°C. Cells were washed three times in 10 volumes of RPMI 1640 at 37°C for
2 h per wash. Untreated schizonts were concentrated to a parasitemia of ;80%
(10) and added to control and lactacystin-treated target cells, so that the starting
parasitemias were ;0.1%. Each treatment was performed in triplicate. Para-
sitemias were measured daily by blind counting of the number of infected
erythrocytes per 2,000 cells on Giemsa-stained blood smears from each flask.
Erythrocyte proteasome isolation. Lactacystin-treated and control erythro-
cytes were treated and washed as for the growth assay described above and then
were washed once in 10 volumes of ice-cold 10 mM Tris–150 mM NaCl, pH 7.5.
The cells were then lysed in 6 ml of ice-cold 10 mM Tris, pH 7.5, and incubated
on ice for 5 min. Three milliliters of 10 mM Tris–800 mM NaCl, pH 7.5, was
added to each tube before ultracentrifugation at 10,000 3 g for 30 min at 4°C
with a Beckman SW-41 rotor and an L8-80 ultracentrifuge. The supernatants
were loaded onto a 1-ml HiTrap Q (Pharmacia) column for anion exchange fast
protein liquid chromatography. Samples were eluted with an NaCl gradient from
200 mM to 1 M in 10 mM Tris, pH 7.5, and 1.2-ml fractions were collected on ice.
Enzymatic assay for proteasome activity. The chymotrypsin-like activities of
HiTrap Q fractions were measured with the fluorescent substrate N-succinyl-
Leu-Leu-Val-Tyr-7-amido-4-methyl-coumarin (Sigma), as described by Gonza-
lez et al. (15).
Quantitative PCR assay for sporozoite infectivity. Plasmodium yoelii sporozo-
ites were incubated with or without 5 mM lactacystin for 1 h at room temperature
and injected intravenously (i.v.) into Swiss Webster mice. Two thousand sporo-
zoites were injected into each mouse, and 40 h later the mice were sacrificed and
their livers were removed. Total RNA extraction from livers and RT-PCR were
performed as described by Briones et al. (2) with 1 mg of RNA. PCR analysis of
this cDNA was performed with parasite rRNA primers that recognize P. yoelii-
specific sequences within the A-type and C-type 18S rRNA. These reactions were
performed in the presence of a competitor template, constructed by insertion of
a 66-bp DNA fragment into the cloned 393-bp rRNA parasite amplification
product. Mouse hypoxanthine phosphoribosyltransferase (HPRT) primers and
competitor were used as positive controls to assess the efficiency of RT reactions
as described previously (26).
Assessment of the effects of lactacystin on malaria infection in rats. Groups of
six Sprague-Dawley rats (Taconic, Germantown, N.Y.), each weighing approxi-
mately 60 g, were infected with P. berghei blood stages and then monitored by
taking blood smears. Treatment with lactacystin started when the average par-
asitemia was approximately 1%. The rats were then distributed into experimental
and control groups, such that the parasitemias of the groups were comparable.
Experimental groups were injected with lactacystin diluted in PBS, while control
groups were injected with PBS alone. Blood smears were counted blindly at the
indicated times after treatment. Data were analyzed by a repeated-measure
analysis of variance (one-tailed test) with SAS software (30). In other experi-
ments, P. yoelii sporozoites were incubated with 3 mM lactacystin or without
lactacystin for 1 h at room temperature and then injected into mice i.v. at the
doses indicated. Blood smears were taken from the mice starting at day 3 and
assessed for the presence of parasites as described above.
RESULTS
Lactacystin inhibits the exoerythrocytic development of P.
berghei in vitro. Table 1 shows that P. berghei sporozoites
treated with lactacystin did not develop normally into EEF.
This inhibition occurred whether the sporozoites were plated
onto HepG2 cells in the presence of the drug (Table 1, exper-
iment 1) or preincubated with the drug and then washed before
being plated onto target cells (Table 1, experiment 2). Prein-
cubation with clasto-lactacystin dihydroxy acid, the inactive
product of lactacystin hydrolysis (9), had no effect. Lactacystin
treatment performed 24 h after the addition of parasites to the
cells (Table 1, experiment 3) still resulted in a significant inhi-
bition of EEF development, and those EEFs that developed
were smaller than normal.
We then tested whether the reduction in the number of EEF
with lactacystin treatment was due to an effect of the drug on
sporozoite invasion of target cells. Sporozoites were preincu-
bated with lactacystin and then added to HepG2 cells. After
1 h, the cells were fixed and a double-staining immunofluores-
cence assay was used to distinguish between intracellular and
extracellular parasites in order to calculate invasion rates.
There was no difference between the invasion rate for control
sporozoites and those for sporozoites preincubated with up to
9 mM lactacystin for 1 h (Table 2). Invasion of host cells by
malaria and other Apicomplexa parasites is an active process
(11, 35, 36). Thus, the observed inhibition of EEF development
by lactacystin was not due to a lethal effect of the drug on
sporozoites.
Since lactacystin did not inhibit cell invasion by sporozoites,
we performed experiments to test whether development of the
parasite was affected by the drug. Characteristic morphologic
TABLE 1. Lactacystin inhibits development of sporozoites
into EEF
Expt Inhibitor Concn (mM) No. ofEEFa
%
Inhibition
1b None 448 6 25
Lactacystin 1 109 6 10 75
3 5 6 2 99
9 0 100
2c None 291 6 5
Lactacystin 1 156 6 6 46




9 280 6 32 6
3d None 816 6 9
Lactacystin 1 574 6 13 29
3 458 6 17 43
9 408 6 3 50
a Number of EEF per 100 high-powered fields.
b Inhibitor present for the first 3 h of the experiment.
c Parasites were preincubated with inhibitor for 1 h, washed, and then plated
on cells.
d Inhibitor was added 24 h after parasites were plated on cells. The EEF in the
lactacystin-treated wells were smaller than those in the control wells.
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changes accompany the development of EEF from sporozo-
ites. Within 4 h after invasion, the middle of the sporozoite
expands into a characteristic bulb-like structure (Fig. 1a) (1).
After 15 h the parasite has a spherical shape (Fig. 1c). If the
sporozoites were treated with lactacystin, none of the parasites
had this bulb-like structure at 4 h after invasion (Fig. 1b). At
15 h, approximately half of the parasites remained as slender
sporozoites inside the cell (Fig. 1d). The other half consisted of
a mixture of round parasites with normal morphology and
parasites with a pyknotic appearance (Fig. 1e).
We also examined the effect of lactacystin on another de-
velopmental marker, namely, the switch in rRNA expression
from C-type sporozoites to A-type EEF. Lactacystin-treated
and control sporozoites were plated on HepG2 cells, and 5 and
21 h later the cells were harvested for quantitative RT-PCR
using C- and A-type-specific rRNA primers. At 5 h, there was
little A-type rRNA in either the lactacystin-treated or control
sporozoites (Fig. 2a). However, at 21 h only control sporozo-
ites showed an increase in the amount of A-type rRNA (Fig.
2b). During this time there was no apparent change in the
amounts of C-type rRNA in lactacystin-treated and control
sporozoites (data not shown).
Effects of lactacystin on P. yoelii EEF development in vivo.
Sporozoites of P. yoelii are, for unknown reasons, significantly
more infectious to mice than those of P. berghei (2) and were
therefore used for in vivo experiments. P. yoelii sporozoites
were preincubated in medium with or without 3 mM lactacystin
and then injected into mice. The mice injected with lactacystin-
treated sporozoites showed an increase in the prepatent period
versus controls (Table 3). As shown, injection of 10,000 or
1,000 lactacystin-treated sporozoites results in the same
prepatent period as the injection of 100 control sporozoites,
suggesting that the drug inhibited development by 90 to 99%
(31).
A more direct quantification of sporozoite infectivity was
performed by means of a competitive RT-PCR assay. When
the amounts of rRNA in the livers of mice injected with control
and lactacystin-treated sporozoites were compared, we found
approximately a 10-fold decrease in the parasite rRNA in mice
injected with treated sporozoites (Fig. 3).
Lactacystin inhibits the growth of P. falciparum erythrocytic
stages in vitro. Figure 4 shows that lactacystin inhibited eryth-
rocytic schizogony, as observed by light microscopy. Normal
trophozoites have a single nucleus (Fig. 4, top left) that divides
a variable number of times to produce the 8 to 26 nuclei
contained in the mature schizont (Fig. 4, top right). Approxi-
mately 90% of the parasites appeared developmentally ar-
rested when treated with 1.25 mM lactacystin (Fig. 4, bottom
left) and persisted for at least 24 h with a morphology that was





Expt 1 Expt 2 Expt 3
0 44 26 27
0 35 28 29
1 46 33
1 51 30
3 50 27 33
3 45 28 33
9 30
9 27
a Sporozoites were incubated with or without lactacystin for 1 h before addi-
tion to HepG2 cells.
b Calculated based on the number of intracellular parasites in 40 to 50 fields/
slide, from the double-staining immunofluorescence assay, 1 h after addition to
HepG2 cells.
FIG. 1. Lactacystin alters the normal development of sporozoites into EEF in vitro. P. berghei sporozoites were incubated in 3 mM lactacystin or medium alone for
15 min and then added to HepG2 cells and allowed to invade and begin their development into EEF. Four and fifteen hours later the cells were fixed and stained with
MAb 3D11 by using the double-staining assay, which allows the distinction between intracellular and extracellular sporozoites. Magnification, 3100.
FIG. 2. Lactacystin inhibits the switch to A-type rRNA of P. berghei in vitro.
Sporozoites were incubated with 3 mM lactacystin or without lactacystin for 15
min and then plated on HepG2 cells. After 2 h, the medium was removed and
fresh medium without inhibitor was added. At 5 (a) and 21 h (b), total RNA was
extracted and RT reactions were performed with 0.1 mg of RNA. Quantitative
PCR of the cDNA was performed with primers specific for A-type rRNA and
serial dilutions of cDNA. The first, second, and third (panel b only) lanes in each
panel show the results of PCR performed with 2, 0.4, and 0.2 ml, respectively, of
cDNA.
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indistinguishable by light microscopy from that of normal tro-
phozoites. At higher concentrations, i.e., 10 mM, however,
many of the parasites showed degenerative changes (Fig. 4,
bottom right).
To exclude the possibility that any of the effects of lactacys-
tin on erythrocytic stage development were due to inhibition of
the erythrocyte’s, rather than the parasite’s, proteasomes, un-
infected erythrocytes were treated with 10 mM lactacystin and
washed extensively. By this method, the chymotrypsin-like ac-
tivity of proteasomes isolated from the treated erythrocytes
was totally inhibited (data not shown). Nevertheless, parasites
grew normally in the lactacystin-treated erythrocytes (data not
shown).
Lactacystin and several lactacystin analogs were also shown
to inhibit the nucleic acid synthesis that occurs during eryth-
rocytic schizogony, as measured by incorporation of [3H]hy-
poxanthine (Fig. 5). Lactacystin spontaneously undergoes lac-
tonization to form clasto-lactacystin b-lactone, the sole
intermediate and active form of the drug, which is then hydro-
lyzed to become the inactive clasto-lactacystin dihydroxy
acid (Fig. 5a) (9). clasto-Lactacystin b-lactone binds irre-
versibly to the amino-terminal threonine of the b subunits,
in the active sites of the proteasome (9, 12). Significant
inhibition occurred at nanomolar concentrations of lacta-
cystin, with approximately 50% inhibition seen at 300 nM
(Fig. 5b). As shown in Fig. 5b and c, clasto-lactacystin b-lac-
tone and the methyl ester analog displayed inhibitory activ-
ities against parasite schizogony identical to that of lacta-
cystin on a molar basis, but clasto-lactacystin dihydroxy acid
was inactive. The 7-ethyl and b-acetylaminoethyl analogs
were slightly more active than lactacystin, while the activi-
ties of the des-7-methyl and the de-N-acetyl analogs were
greatly reduced.
When tested on proteasomes isolated from human erythro-
cytes, several of these lactacystin analogs showed inhibitory
activities relative to lactacystin that paralleled their activities
against Plasmodium schizogony (Fig. 5d). Specifically, the in-
hibitory activity of 7-ethyl-lactacystin was increased compared
to that of lactacystin, while that of des-7-methyl lactacystin was
greatly reduced. However, the b-acetylaminoethyl analog had
activity which was identical to that of lactacystin in this assay,
in contrast to its greater potency in the inhibition of [3H]hy-
poxanthine uptake by the parasites.
We then tested the effect of lactacystin on the parasite at
different stages of the erythrocytic cycle. Synchronized para-
sites at 18 h of the cycle were plated into triplicate wells and
[3H]hypoxanthine, with or without lactacystin, was added at
successive time points. All cells were harvested at the end of
the 48-h cycle, and incorporated radioactivity was measured.





No. of mice positive for









100 None 0/3 3/3
Lactacystin 0/3 0/3 2/3c
a Sporozoites were preincubated in medium with 3 mM lactacystin or without
lactacystin for 1 h and then injected into mice i.v.
b On days 3 to 5 postinjection blood smears were taken from mice and ana-
lyzed for the presence of parasites.
c The mouse that was negative on day 5 remained negative for the next 7 days.
FIG. 3. Lactacystin decreases sporozoite infectivity in vivo. P. yoelii sporozo-
ites were incubated in 5 mM lactacystin or medium alone for 1 h. Two thousand
sporozoites were then injected i.v. into each mouse, and 40 h later the mouse
livers were harvested for isolation of RNA. Sporozoite infectivity was quantified
by measuring the amount of parasite rRNA in a quantitative RT-PCR assay. The
top two panels show PCRs performed with P. yoelii rRNA primers and 1 and 0.1
pg of a P. yoelii rRNA competitor. The parasite target band is 393 bp, and that
of the competitor is 459 bp. The bottom panel shows control PCRs performed
with the same RT reaction mixtures containing HPRT primers and 0.04 pg of an
HPRT competitor; the HPRT target band is 352 bp, and that of the competitor
is 450 bp. M 5 markers (1,000, 750, 500, 300, and 150 bp).
FIG. 4. Lactacystin inhibits the development of P. falciparum erythrocytic
stages in vitro. Photomicrographs were taken of synchronized trophozoites at
18 h (top left), after which the trophozoites were incubated for another 24 h in
either medium alone (top right) or 1.25 (bottom left) or 10 mM (bottom right)
lactacystin.
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The value for each time point, therefore, represents the
amount of nucleic acid synthesis that occurred from that time
until the end of the erythrocytic cycle. Figure 6 shows that
when lactacystin was added during the first 30 h of the para-
site’s cycle, [3H]hypoxanthine incorporation was inhibited. In
contrast, inhibition of [3H]hypoxanthine incorporation was no
longer seen when parasites were treated later, after 30 h and
throughout schizogony.
Effects of lactacystin on P. berghei erythrocytic stages in
vivo. Figure 7 shows that, for rats infected with P. berghei
erythrocytic stages in erythrocytic stages, treatment with one
dose of 1.6 mg of lactacystin resulted in a significant (P 5 0.05)
reduction of parasitemia in comparison with that of controls,
as calculated by a one-tailed repeated-measure analysis of vari-
ance. Treatment with a total of 4 mg of lactacystin per rat,
given as three i.v. injections of 1.3 mg each, 8 h apart, cleared
FIG. 5. Lactacystin analogs inhibit P. falciparum erythrocytic stages and isolated human proteasomes similarly. (a) Chemical structures of lactacystin and the analogs
studied. (b and c) Synchronized trophozoites at 18 h of the erythrocytic cycle were plated in 96-well microtiter plates with [3H]hypoxanthine and the concentrations
of inhibitors indicated. After 24 h, cells were harvested and incorporation of the label was measured. Shown are the means of triplicate wells 6 standard deviations.
(d) Proteasomes isolated from normal human erythrocytes, plus inhibitors at the indicated concentrations, were incubated with fluorogenic substrate N-succinyl-Leu-
Leu-Val-Tyr-7-amido-4-methyl-coumarin to measure chymotrypsin-like activity. Each point is the mean of the fluorescences of duplicate wells 6 the standard deviation.
Symbols (panels b, c, and d): solid circles, lactacystin; open circles, clasto-lactacystin b-lactone; open upright triangles, b-acetylaminoethyl lactacystin; open diamonds,
de-N-acetyl lactacystin; solid triangles, clasto-lactacystin dihydroxy acid; open hexagons, 7-ethyl lactacystin; open inverted triangles, des-7-methyl lactacystin; open
squares, methyl ester lactacystin.
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infection (data not shown). However, none of the five rats
treated survived this regimen.
DISCUSSION
We show here that lactacystin, a proteasome inhibitor,
blocks the development of the preerythrocytic and erythrocytic
stages of Plasmodium spp. Lactacystin covalently modifies the
catalytic N-terminal threonines of the active sites of protea-
somes, inhibiting the activities of all proteasomes examined
including those of mammalian cells (6, 9, 12, 16), protozoa (14,
15), and archaea (23). It is therefore highly unlikely that pro-
teasomes of Plasmodium are not inhibited by lactacystin. In
addition, lactacystin is an exquisitely specific drug: it does not
inhibit any other known proteases (12). When [3H]lactacystin
was incubated with whole-mammalian-cell extracts or with
crude brain extracts, radioactivity was associated exclusively
with proteasome subunits (12). For these reasons, we chose
lactacystin, and analogs thereof, to examine the role of pro-
teasomes in the development of Plasmodium.
Lactacystin-treated sporozoites, although invasive in vitro,
did not round up normally and acquire the characteristic EEF
morphology. This finding was supported by using a molecular
marker for EEF development: the switch from C-type to A-
type rRNA expression. Plasmodium spp. are unique in that
they express different rRNAs in different stages of their life
cycles (37). Although small amounts of all rRNA types can
always be found in each stage, the vast majority of rRNA in
sporozoites is C-type rRNA. After the parasites invade hepa-
tocytes, they begin to synthesize A-type rRNA, and by 20 h
after invasion this is the predominant rRNA associated with
the parasites. When sporozoites were treated with lactacystin,
no increase in A-type rRNA could be detected at 20 h. In
addition, sporozoite development in vivo appeared to be in-
hibited by lactacystin, as treated sporozoites were at least 10-
fold less infective in mice.
Starting between 30 and 40 h after erythrocyte invasion,
trophozoites go through several rounds of DNA replication
and nuclear division as they develop into merozoite-containing
schizonts. Lactacystin-treated trophozoites, however, did not
transform into schizonts. They maintained an arrested but ap-
parently normal morphology for extended periods (Fig. 4,
lower left), similar to what was observed with lactacystin-
treated sporozoites within HepG2 cells (Fig. 1d). The addition
of lactacystin up to 30 h after erythrocyte infection strongly
inhibited [3H]hypoxanthine incorporation, but the drug had no
effect after the beginning of schizogony (Fig. 6). Thus, only the
initiation of DNA synthesis was prevented by lactacystin, and
not DNA synthesis per se.
A trivial explanation for the lack of inhibitory effect of lac-
tacystin treatment during schizogony might be that the protea-
somes of late stages of the parasite are inaccessible to the drug.
This is unlikely, however, since the lactacystin-treated schi-
zonts were also developmentally arrested: although they ap-
peared normal by light microscopy and incorporated [3H]hy-
poxanthine normally, they did not rupture (data not shown).
The mechanisms by which lactacystin inhibits Plasmodium de-
velopment are not known, but an attractive possibility is that
the drug affects the control of cell cycle progression in the
parasite. Proteasome activity is required for transition through
the G1/S boundary and for exit from M phase in a number of
cell types (20). Cell cycle control in Plasmodium is poorly
understood. However, the inhibition of the onset of DNA
synthesis and the lack of schizont rupture seen with lactacystin
treatment may be due to similar requirements for proteasome
activity in the cell cycle progression of Plasmodium.
In an attempt to find a potent parasiticidal drug, we tested
several analogs of lactacystin. As shown by the [3H]hypoxan-
thine uptake assay, two analogs were consistently more potent
inhibitors than clasto-lactacystin b-lactone in this assay: 7-ethyl
FIG. 7. Lactacystin significantly reduces parasitemia in vivo. Six P. berghei-
infected rats were paired into two groups of three rats; all rats had comparable
parasitemias. Each rat in the experimental group (open circles) received 1.6 mg
of lactacystin in 1 ml of PBS, given as one intraperitoneal injection of 0.5 ml and
one i.v. injection of 0.5 ml at the same time. Each rat in the control group (solid
circles) received identical injections of PBS alone. Giemsa-stained blood smears,
taken at the time points indicated, were blindly counted to measure parasitemias.
Each point represents the mean of parasitemias from three rats 6 the standard
deviation.
FIG. 6. Lactacystin inhibits DNA synthesis in a stage-specific manner. Syn-
chronized trophozoites were plated in 96-well microtiter plates at 18 h into the
erythrocytic cycle. [3H]hypoxanthine with (open circles) or without (closed cir-
cles) lactacystin was added to wells at the times indicated. All cells were har-
vested at 48 h in the cycle, and incorporation of the label was measured. Shown
are the means of triplicate wells with standard deviations.
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lactacystin and b-acetylaminoethyl lactacystin (Fig. 5b and c).
An analysis of the structure of the yeast proteasome cocrystal-
ized with lactacystin revealed that, in addition to the presence
of several hydrogen bonds between the drug and the b5/PRE2
subunit, the isopropyl group on C-10 of lactacystin is inserted
into the S1 (“specificity”) pocket of the enzyme active site (16).
7-Ethyl lactacystin has one more carbon on the g-lactam ring
than lactacystin, i.e., it has an ethyl group instead of a methyl
group at C-7. Since des-7-methyl lactacystin lacks the methyl
group at C-7 (Fig. 5a) and shows greatly decreased activity
(Fig. 5b), our findings highlight the importance of C-7 side
chains for acylation of the proteasome.
The other analog with increased activity, b-acetylaminoethyl
lactacystin, is modified only on the N-acetylcysteine moiety.
This is unexpected since the N-acetylcysteine moiety is lost
during lactonization into the active compound, clasto-lactacys-
tin b-lactone. The reasons for the increase in activity are there-
fore not clear. It is thought that cells are impermeable to
lactacystin and that only the b-lactone enters cells (8). One
possibility is that the b-acetylaminoethyl analog can enter cells
prior to lactonization. The increased hydrophobicity resulting
from the removal of the carboxyl group of lactacystin to form
b-acetylaminoethyl lactacystin might facilitate passage through
the plasma membranes of cells.
When tested on proteasomes isolated from human erythro-
cytes, several analogs showed activities relative to that of lac-
tacystin that paralleled those found in the P. falciparum
[3H]hypoxanthine uptake assay (Fig. 5d). The only exception
was the b-acetylaminoethyl analog, which as expected had the
same potency as lactacystin on isolated proteasomes (see
above). The observation that most lactacystin analogs do not
discriminate between the mammalian and parasite protea-
somes suggests that the active sites of these enzymes are sim-
ilar. In agreement with these in vitro observations, lactacystin
effectively inhibited parasite growth in vivo, but its therapeutic
index precludes clinical usefulness. Several other classes of
potent proteasome inhibitors exist (reviewed in reference 5),
and it is hoped that those currently being developed will be
more selective for the parasite proteasome. The identification
of drugs that can exploit differences between the parasite and
host proteasomes should be facilitated by the isolation and
structural characterization of the proteasome of Plasmodium.
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